CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-09-02): HBV vaccine nonresponders may respond to combined Hep A/B vaccine

Clinical

HBV vaccine nonresponders may respond to combined Hep A/B vaccine

Last Updated: 2008-09-02 9:37:41 -0400 (Reuters Health)

NEW YORK (Reuters Health) - For the 5% to 10% of adults who fail to mount an adequate response to the standard hepatitis B virus (HBV) vaccine regimen, a double dose of the combined hepatitis A and B vaccine may turn these nonresponders into responders, results of a study from Sweden suggest.

Most guidelines recommend a repeated course of the standard HBV vaccine in people who fail to develop protective levels of antibodies to hepatitis B surface antigen (anti-HBs).

Instead of repeating the standard HBV vaccine regimen in nonresponders, Dr. Kristina Cardell from University Hospital, Linkoping and colleagues opted to administer the combined hepatitis A and B vaccine. Their study involved 48 healthcare workers who failed to respond to the HBV vaccine and 20 control subjects na�ve to the HBV vaccine.

After the first dose of the combined vaccine, protective levels of anti-HBs were achieved in 59% of HBV vaccine nonresponders and 10% of control subjects, the investigators report in the August 1 issue of the Journal of Infectious Diseases. After 3 doses, 95% of prior nonresponders and 100% of controls had developed a response.

"This is most likely explained by the increased dose, a positive bystander effect conferred by the hepatitis A vaccine, or both," Dr. Cardell and colleagues say.

In a commentary, Dr. Helmut M. Diepolder from University of Munich, Germany, writes, "These results are among the best achieved in comparable studies using revaccination with the standard hepatitis B vaccine and are comparable to results from revaccination studies using the pre-S1/S2 vaccine or vaccines with new adjuvants."

"Importantly, the combined vaccine was well tolerated and is, thus, an interesting option to use in hepatitis B nonresponders who are negative for antibodies to hepatitis A virus," Dr. Diepolder adds.

J Infect Dis 2008;198:297-304.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.